Distinctive 'qualifier' for all biologics could solve biosimilar INN dispute
This article was originally published in SRA
Executive Summary
A compromise proposal being discussed this week by the World Health Organization's expert group on international non-proprietary names (INNs) could help to settle the dispute between originator and biosimilar companies as to whether biosimilars should have a distinguishable INN from that of their reference product.